If you have been reading about trans-3-hexenoyl and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-10-04. Where a claim depends on a specific study, the study is described rather than over-claimed.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue peptide | GHRH analog backbone |
| Approximate molecular mass | 5136 Da | Varies with counterion and hydration state |
| N-terminal group | trans-3-hexenoyl | Increases resistance to dipeptidyl peptidase IV |
| Primary receptor | GHRH receptor (GHRHR) | Class B G protein-coupled receptor on somatotrophs |
| Principal mediator | IGF-1 | Rises indirectly after growth hormone release |
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
Constancy testing is the verification of reference values as part of quality assurance in x-ray diagnostics, nuclear medicine diagnostics, and radiotherapy. National regulations specify which parameters are to be tested, which limits are to be observed, which test methods are to be used, and which test samples are to be used. In Germany, the Radiation Protection in Medicine Directive and the relevant DIN 6855 standard in nuclear medicine require regular (in some cases daily) constancy testing. Test sources are used to check the response of probe measuring stations as well as in vivo and in vitro measuring stations. Before starting the tests, the background count rate and the setting of the energy window must be checked every working day, and the settings and the yield with reproducible geometry must be checked at least once a week with a suitable test source, e.g. 137Caesium (DIN 6855-1). The reference values for the constancy test are determined during the acceptance test. Compact test specimens for medical X-ray images were not created until 1982. Prior to this, the patient himself often served as the object for producing X-ray test images. Prototypes of such an X-ray phantom with integrated structures were developed by Thomas Bronder at the Physikalisch-Technische Bundesanstalt. A water phantom is a Plexiglas container filled with distilled water that is used as a substitute for living tissue to test electron linear accelerators used in radiation therapy.
== Life == Roderich Süssmuth studied chemistry and biochemistry at the Eberhard Karls University of Tübingen from 1990 to 1996. In 1999, he received his doctorate under Günther Jung in Tübingen with a dissertation entitled Isolation, structural elucidation, and synthesis of microbial metabolites from Amycolatopsis mediterranei, Staphylococcus epidermidis, and Streptomyces lividans. During a postdoctoral stay at the Scripps Research Institute in La Jolla, California, United States, from 2000 to 2001, he worked with Richard A. Lerner and Carlos F. Barbas on catalytic antibodies and organocatalysis. As an Emmy Noether Research Fellow (DFG) from 2001 to 2004, he completed his habilitation in chemistry and biochemistry at the University of Tübingen. In 2004, he was appointed Associate Professor of Biological Chemistry at TU Berlin. In 2008, he was appointed to the Rudolf Wiechert Professorship of Biological Chemistry at TU Berlin. In 2020, he was named a Fellow of the Royal Society of Chemistry (FRSC) and an honorary member of the Israel Chemical Society. In 2022, he was admitted to the Confraternity of Santa Maria dell'Anima in Rome.
== Interactions == Besides integrin, fibronectin binds to many other host and non-host molecules. For example, it has been shown to interact with proteins such fibrin, tenascin, TNF-α, BMP-1, rotavirus NSP-4, and many fibronectin-binding proteins from bacteria (like FBP-A; FBP-B on the N-terminal domain), as well as the glycosaminoglycan, heparan sulfate. pUR4 is a recombinant peptide that is known to inhibit the polymerization of fibronectin in a number of cell types including fibroblasts and endothelial cells. Fibronectin has been shown to interact with:
Benzodiazepines share a similar chemical structure, and their effects in humans are mainly produced by the allosteric modification of a specific kind of neurotransmitter receptor, the GABAA receptor, which increases the overall conductance of these inhibitory channels; this results in the various therapeutic effects as well as adverse effects of benzodiazepines. Other less important modes of action are also known. The term benzodiazepine is the chemical name for the heterocyclic ring system (see figure to the right), which is a fusion between the benzene and diazepine ring systems. Under Hantzsch–Widman nomenclature, a diazepine is a heterocycle with two nitrogen atoms, five carbon atom and the maximum possible number of cumulative double bonds. The "benzo" prefix indicates the benzene ring fused onto the diazepine ring. Benzodiazepine drugs are substituted 1,4-benzodiazepines, although the chemical term can refer to many other compounds that do not have useful pharmacological properties. Different benzodiazepine drugs have different side groups attached to this central structure. The different side groups affect the binding of the molecule to the GABAA receptor and so modulate the pharmacological properties. Many of the pharmacologically active "classical" benzodiazepine drugs contain the 5-phenyl-1H-benzo[e][1,4]diazepin-2(3H)-one substructure (see figure to the right). Benzodiazepines have been found to mimic protein reverse turns structurally, which enables them to exert their biological activity in many cases.
==== National honors ==== Knight Grand Cross of Rizal (KGCR) – (2017) Awards for Promoting Philippines-China Understanding (APPCU), Hall of Fame – (2023) Integrated Bar of the Philippines Golden Pillar of Law Award – (2025)
Sources: en.wikipedia.org
Ampika Pickston (born 23 July 1981) is an English model, reality TV star and business owner. She starred in The Real Housewives of Cheshire from 2015 to 2017. Pickston is the CEO of Ampika's Aesthetics, a training school based in Hale, Greater Manchester, which teaches aesthetic procedures.
Other compounds other than radiolabelled somatostatin receptor antagonists have also been studied. Cyclosomatostatin is one such compound. Contrary to previously discussed compounds, cyclosomatostatin does not contain a radionuclide. It is a non-selective somatostatin receptor antagonist, inhibiting the effects of somatostatin on target cells in the gastrointestinal (GI) tract, pancreas, hypothalamus, and central nervous system (CNS). Cyclosomatostatin is used as a research chemical to investigate the effects of somatostatin on different cell types by antagonizing its receptors. However it acts as an agonist in SH-SY5Y neuroblastoma cells. Cyclosomatostatin is also known by the following names:
After graduating with a degree in theater from Towson University in 2003 and moving to New York City, Schumer portrayed a young woman diagnosed with breast cancer in the Off-Off-Broadway black comedy Keeping Abreast. She started doing stand-up comedy on June 1, 2004, when she first performed at Gotham Comedy Club. A few years later, she and Kevin Kane co-founded The Collective, which is a theater group that publishes and performs socially relevant and accessible work. In 2007, Schumer recorded a Live at Gotham episode for Comedy Central before appearing on Last Comic Standing; she later recalled that she thought of the episode as her "big break". Rebounding from an unsuccessful audition for an earlier season, she advanced to the finals of the fifth season of the NBC reality television talent show Last Comic Standing and placed fourth. Schumer said in April 2011, "Last Comic was totally fun. I had a great time because there was no pressure on me; I had been doing stand-up around two years. I wasn't supposed to do well. So every time I advanced it was a happy surprise. I kept it honest on the show and it served me well." Schumer co-starred in the Comedy Central reality show Reality Bites Back in 2008. In 2009, she appeared in an advertising campaign for Butterfinger. Schumer was a recurring guest on Fox News late-night program Red Eye w/ Greg Gutfeld between 2007 and 2012. Her first Comedy Central Presents special aired on April 2, 2010. She served as a co-host of A Different Spin with Mark Hoppus in 2011, later titled Hoppus on Music. She has also written for Cosmopolitan.
== Use in synthesis reactions == D-amino acid dehydrogenase has shown itself to be effective in the synthesis of branched-chain amino acids such as D-leucine, D-isoleucine, and D-valine. In the given study, researchers were successfully able to use D-amino acid dehydrogenase to create high amounts of these products from the starting material of 2-oxo acids, in the presence of ammonia. The conditions for this were variable, though the best results appeared at around 65 °C. Amino Acids obtained through these reactions resulted in a high enantioselectivity of >99% and high yields of >99%. Given the nature of this enzyme, it may be possible to use it in order to create non-branched D-amino acids as well as modified D-amino acids.
Sources: en.wikipedia.org
The amino acid sequence matches human growth hormone-releasing hormone, but the amino terminus carries a trans-3-hexenoyl group instead of a free amine. That single structural change chiefly affects enzymatic stability rather than receptor selectivity.
Growth hormone released from the pituitary stimulates IGF-1 production in the liver and other tissues, so circulating IGF-1 generally rises during exposure. The size of the rise varies between individuals and depends on baseline hormonal status and other concurrent factors.
Reported imaging studies focus on visceral adipose tissue, where reductions are more consistently observed across trials. Subcutaneous depots show smaller and less reproducible changes, so the two compartments should not be treated as equivalent.
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.